An unhealthy year
During Q4 2016, the pharmaceutical laboratory’s revenues declined by 9% to TND23.328m, pulled down mainly by a yoy drop of 11.9% in branded products’ revenues as well as a decrease in export sales, reaching TND0.151m against TND0.8m a year earlier. Nevertheless, sales to hospitals increased by 50% to TND1.234m. Q4 2016 production was up 12.8% to 5.677 million units.Adwya ended the year with a 4.8% sales decline on the back of a regression in almost all product lines, namely branded products (-5.6% to TND49.9m), hospital products (-15.2% to TND3.61m) as well as export revenues which were reduced by half.
AlphaMena is the MENA stocks leader in independent equity research, covering 142. MENA securities spanning across 19 sectors and 8 countries relaying on a team of 11 analysts. The breadth of coverage allows AlphaMena to formulate a coherent view on markets, sectors and to highlight the best investments in Mena zone using a robust homogeneous and transparent methodology, enabling pure and pertinent comparisons based on financial and extra-financial criteria.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.